Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 5,921 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Completed Phase 2 Interventional Results available

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

NCT03025698
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Eltrombopag, hATG, CsA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 4:47 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

NCT05266898
View directory record Official record
Conditions
Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
Interventions
Human papillomavirus 9-valent vaccine, recombinant, human papillomavirus vaccine, recombinant
Biological
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 30, 2026, 4:47 PM EDT
Completed No phase listed Observational

Vasculitis Illness Perception (VIP) Study

NCT02190916
View directory record Official record
Conditions
Wegener Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Polyarteritis Nodosa, Giant Cell Arteritis, Takayasu's Arteritis, Henoch-Schoenlein Purpura, Behcet's Disease, CNS Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 15, 2014 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

Safety and Biomarker Response to (+)-Epicatechin in Becker Muscular Dystrophy

NCT04386304
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
(+)-Epicatechin
Drug
Lead sponsor
Epirium Bio Inc.
Industry
Eligibility
16 Years to 59 Years · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Sacramento, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of an Oral Supplement in Supporting Vision and Eye Health

NCT07123584
View directory record Official record
Conditions
Dry Eye, Eye Fatigue
Interventions
Eye Empower, Placebo
Dietary Supplement
Lead sponsor
Bio Nature Health
Industry
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 1 Interventional

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

NCT00741234
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
Interventions
SB939, Azacitidine
Drug
Lead sponsor
S*BIO
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Houston, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation

NCT01484964
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
Interventions
ASP015K
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

NCT01994109
View directory record Official record
Conditions
Sialorrhea
Interventions
MYOBLOC, PLACEBO
Drug · Other
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
24
States / cities
Loma Linda, California • Los Angeles, California • National City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 30, 2026, 4:47 PM EDT
Recruiting Not applicable Interventional

Bright Ideas - CIN Feasibility Study

NCT04929899
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Bright Ideas - CIN Training
Behavioral
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
4 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Los Angeles, California • New Brunswick, New Jersey • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects

NCT01287858
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AC430
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Oral Cladribine in Early Multiple Sclerosis (MS)

NCT00725985
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Rebif® new formulation (RNF)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 30, 2026, 4:47 PM EDT
Withdrawn Phase 2 Interventional

A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma

NCT02402725
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Results available

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT02780804
View directory record Official record
Conditions
Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Recurrent Visual Pathway Glioma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Refractory Visual Pathway Glioma
Interventions
Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

NCT01625234
View directory record Official record
Conditions
Advanced Solid Tumors, Non-small Cell Lung Cancer
Interventions
Phase I: X-396 (ensartinib), Phase II: X-396 (ensartinib)
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
14
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 30, 2026, 4:47 PM EDT
Terminated Phase 3 Interventional Results available

LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research

NCT02231164
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
docetaxel, placebo, nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
9
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Highland, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

NCT04903093
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Cox-2 Inhibition in Radiation-induced Oral Mucositis

NCT00698204
View directory record Official record
Conditions
Oral Mucositis
Interventions
celecoxib, placebo
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Farmington, Connecticut • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

NCT02212678
View directory record Official record
Conditions
Parkinson Disease
Interventions
N-acetylcysteine capsule
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 30, 2026, 4:47 PM EDT
Terminated Phase 3 Interventional Results available

Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease

NCT00530270
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Sacramento, California • Louisville, Kentucky • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 3 Interventional

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

NCT00006145
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Valganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
56
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

Cleft Palate Surgery and Speech Development

NCT00004639
View directory record Official record
Conditions
Cleft Lip, Cleft Palate
Interventions
Furlow double z-plasty palatoplasty palate repair, Von Langenbeck palatoplasty palate repair
Procedure
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

NCT05644977
View directory record Official record
Conditions
Healthy Participants, Alzheimer's Disease Dementia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
11
States / cities
Cypress, California • San Diego, California • Hialeah, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 30, 2026, 4:47 PM EDT
Active, not recruiting Phase 1 Interventional

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

NCT04891757
View directory record Official record
Conditions
Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia
Interventions
FHD-286, Low Dose Cytarabine, Decitabine
Drug
Lead sponsor
Foghorn Therapeutics Inc.
Industry
Eligibility
16 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 30, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assessing the Analgesic Efficacy of Naproxen Sodium in Postsurgical Dental Pain.

NCT00720057
View directory record Official record
Conditions
Toothache
Interventions
Naproxen Sodium ER (BAYH6689), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 30, 2026, 4:47 PM EDT